Pakistan Republic’s Post

For patients with severe emphysema, stereotactic irradiation for lung volume reduction (SILVR) appears to be safe, with a signal for efficacy as a novel therapeutic alternative, according to a clinical trial by Kamtam et al. Eligible patients were treated with unilateral stereotactic ablative radiation therapy (45 Gy in 3 fractions) to a target within the most emphysematous region. The primary outcome was safety in terms of incidence of grade ≥3 adverse events, and the secondary outcome was efficacy. An 18 month follow-up was reported. You can read our summary blog on this trial on the IORBC website, which also contains a link to the full clinical investigation ⬇️ https://lnkd.in/evBDFkqT #radiotherapy #radiation #emphysema

As we continue to tighten margins and escalate doses in highly conformal radiotherapy treatments today, safety and accuracy is key. This also becomes increasingly important when we are treating in areas subjected to motion. Join us in this upcoming webinar series where clinical experts from around Asia Pacific, Japan and India share their best practices, “tips & tricks”, and how advanced imaging and motion management modules on the TrueBeam and Halcyon platforms support high quality radiation therapy treatments.   Block your calendar for the first session coming to you this May 27th where clinical experts from Australia and Japan share their insights; covering complex and unique case scenarios in liver and prostate SBRT treated on the TrueBeam platform. More details to come in the following weeks.

🇧🇪 Thrilled to Announce the Launch of the BELGICA Study! 🧠 I am happy to share that our randomized study, BELGICA, has received funding from the KCE! BELGICA will evaluate whether delivering radiotherapy in a more focused manner for patients with glioblastoma can reduce side effects and improve quality of life. The study will be opened in 23 centers across Belgium. This project originates from the Belgian Radiation Oncology Group (BROG) and will be sponsored by Cliniques universitaires Saint-Luc. A special thanks to: -The members of the BROG Neuro-Oncology Working Group for their help in the development of the study: Tom Boterberg, Jean-François Daisne, Maarten Lambrecht, Martinive Philippe, Paul Meijnders. -The 23 collaborating centers across Belgium for their enthusiasm in joining the project. -The Clinical Trial Centre, under the direction of Dominique Van Ophem, for their continuous support and expertise: Floriane Adriaens, Elise Bays, Isabelle Beaufay, Alix. Collard, Kevin Pilger, Benoît Plichon, Aline van Maanen. -Our funder, KCE Trials, for believing in the importance of this research. I am also happy to welcome Chloë De Laet as project manager for BELGICA!

First study ever to be launched via the B-ROG platform. Congratz Dario DI PERRI et al! 👍🍀❤️ The Belgian Radiation Oncology Group (B-ROG) is the research plateform of the Belgian SocieTy of Radiation-Oncology (BeSTRO). It is devoted to the promotion, the development and the coordination of Belgian (academic) research in radiation oncology. The aim is not to replace the already existing (and often larger) structures like EORTC but rather to aim at complementing them in Belgian peculiarities of the academic landscape. It also does not aim to concentrate academic research in the solely academic departments but rather to foster it in all Belgian radiation oncology departments willing to develop a patient-centric, non-industry driven research of quality in Belgium. B-ROG has a TRIPLE AIM: • Collaboration to do studies better & faster • Common application for funding • Increase the global quality of Belgian RT More information an be found on www.bestro.be #Radiotherapy #RadiationOncology #Oncology #BROG #BeSTRO #KCE #OncologyCare #StrategicPlanning #Collaboration #PatientCentricity #oncology #cancer #cancercenter #OECI #CancerCare #CancerCenter

KCE Trials is delighted to announce the funding of the BELGICA study: achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume (KCE-231426). This study seeks to determine whether radiotherapy could be given in a more focused manner, safely reducing the Clinical Target Volume to decrease the volume of brain being irradiated and therefore decrease treatment toxicity, in patients with glioblastoma. The investigators hope this will be as effective while reducing side effects and improving quality of life.   Congratulations to the Sponsor Cliniques universitaires Saint-Luc and the Chief Investigator Dr. Dario DI PERRI. The study aims to recruit 347 participants in 23 sites.   More info on the study on the KCE website: https://lnkd.in/eyxXi-4e   #KCETrials #ClinicalTrials #ClinicalResearch

🚀 Advancing Cancer Treatment: The Impact of Proton Therapy 🚀 Proton therapy is not just a breakthrough in cancer treatment; it’s transforming lives and boosting productivity. Patients undergoing proton therapy can return to work more quickly, contributing to society and the economy. 🌟 KEY HIGHLIGHTS: • About 20% of cancer patients could benefit significantly from proton therapy. • MD Anderson Cancer Center’s new center features cutting-edge technology with real-time tumor tracking and three-dimensional imaging. • The number of proton therapy centers in the U.S. is limited due to high costs, but advancements are making these facilities more accessible. This is a global trend, with rapid growth expected over the next two decades. Ensuring access for patients aged 21-40, including those with testicular or cervical cancer, is a current focus to ensure equitable treatment availability. As technology advances, proton therapy is becoming a more viable and widespread option, promising better outcomes and broader access for patients around the world. 🌍 See the full article featuring Dr. Steven Frank: https://lnkd.in/gjRK7Sdf #ProtonTherapy #CancerTreatment #HealthcareInnovation #MDAnderson #CancerResearch #MedicalAdvancements #EquitableHealthcare

We must admit: we were not the first ones... Let's take a moment today to appreciate tremendous work of our predecessor, the #QuADRANT #EUFunded tender 🙇♂️ ➡️ QuADRANT evaluated the levels of #BSSD compliance and the development of supporting clinical audit processes to improve #ClinicalAudit broader implementation and foster its full integration into existing audit programmes in healthcare. ➡️ QuADRANT prepared a set of guidelines and recommendations which were submitted to the European Commission ➡️ The European Commission adopted recommendations on clinical audits of medical radiological practices in April 2024 👏 The recommendations are the result of the collaborative work between QuADRANT, the Heads of the European Radiological Protection Competent Authorities (HERCA), and the SAMIRA Steering Group on Quality and Safety and the European Commission. 👉 Curious to learn more about the QuADRANT project and its success? https://lnkd.in/dz2g2hmS European Commission | European Society of Radiology | European Association of Nuclear Medicine (EANM) | European Society for Radiotherapy and Oncology (ESTRO) #EU4Health #EUCancerPlan #HealthUnion

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/gBCCExRZ #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/er5At2wT #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/gZAxiCvH #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.